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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYAge-related macular degeneration (AMD) causes severe visual impairment due in part to age-dependent impairment of retinal pigment
epithelium (RPE). It has been suggested that autologous human induced pluripotent stem cells (hiPSCs)may represent a useful cell source
for the generation of graft RPE. We generated hiPSC-derived RPE (hiPSC-RPE) cell sheets optimized to meet clinical use requirements,
including quality, quantity, consistency, and safety. These cell sheets are generated as amonolayer of cells without any artificial scaffolds,
express typical RPE markers, form tight junctions that exhibit polarized secretion of growth factors, and show phagocytotic ability and
gene-expression patterns similar to those of native RPE. Additionally, upon transplantation, autologous nonhuman primate iPSC-RPE
cell sheets showed no immune rejection or tumor formation. These results suggest that autologous hiPSC-RPE cell sheets may serve as
a useful form of graft for use in tissue replacement therapy for AMD.INTRODUCTION
Age-related macular degeneration (AMD) (Bressler et al.,
1988) is a leading cause of severe visual impairment in
elderly persons in developed countries and is character-
ized by progressive degeneration of the retinal pigment
epithelium (RPE). RPE consists of a monolayer of cells sit-
uated between the photoreceptors and the choroid, and
plays essential roles in photoreceptor maintenance, such
as supplying nutrition, formation of the blood-retinal bar-
rier, and phagocytosis of mature outer rod segments shed
by photoreceptors (Young and Bok, 1969), as well as in
the maintenance of choroidal circulation by the secretion
vascular endothelial growth factor (VEGF) from its basal
aspect. Current therapies for AMD show only limited effi-
cacy, and in recent years increasing attention has been
given to the replacement of pathological RPE with
healthy tissue. To date, transplantation of allogeneic fetal
RPE (Algvere et al., 1994) or autologous peripheral RPE
(Binder et al., 2002; van Meurs and Van Den Biesen,
2003) has been reported in AMD patients, although
neither represents an ideal tissue source; fetal tissue is
immunogenic, while the latter requires RPE to be har-
vested by an invasive procedure. Human induced pluripo-
tent stem cells (hiPSCs) (Takahashi et al., 2007) exhibit
a number of clinically attractive features, including the
potential to serve as an autologous cell source through
reprogramming of a patient’s own somatic cells, and the
ability to self-renew and expand in culture, and to differ-
entiate into RPE.Stem CellIn RPE transplantation, it is widely accepted that grafted
cells perform better in terms of their morphology, physi-
ology, and survival when transplanted as sheets rather
than in suspension. It appears that environmental fac-
tors provided by cell sheets, such as extracellular matrix
and adhesion molecules, help to prevent apoptosis (Tezel
and Del Priore, 1997). Previous studies generated RPE
cell sheets using various artificial scaffolds (Bhatt et al.,
1994; Lee et al., 2002); however, biodegradable materials
may cause inflammation, and nondegradable membranes
may separate the RPE from the underlying choroid that
nourishes the RPE and photoreceptors. To date, there
have been no published reports of RPE cell sheets gener-
ated without any artificial scaffold, although cell sheets
that do not use an artificial scaffold have been generated
from various other cell types, such as cornea (Nishida
et al., 2004), cardiac myoblast (Shimizu et al., 2001), and
hepatocyte (Harimoto et al., 2002), for use in clinical
studies.
We previously reported the induction of RPE from both
embryonic stem cells (ESCs) (Haruta et al., 2004; Kawasaki
et al., 2002; Osakada et al., 2008; Thomson et al., 1998)
and iPSCs (Jin et al., 2012; Hirami et al., 2009). In the
present study, we assessed the quality, quantity, consis-
tency, and safety of clinical-grade hiPSC-RPE cell sheets
eliminating the need for artificial scaffolds by examining
their morphology, function in vitro and in vivo, and gene
expression. We additionally compared the immunoge-
nicity of autologous and allogeneic iPSC-RPE grafts in a
nonhuman primate.Reports j Vol. 2 j 205–218 j February 11, 2014 j ª2014 The Authors 205
(legend on next page)
206 Stem Cell Reports j Vol. 2 j 205–218 j February 11, 2014 j ª2014 The Authors
Stem Cell Reports
Human iPSC-RPE Cell Sheets for Clinical Therapy
Stem Cell Reports
Human iPSC-RPE Cell Sheets for Clinical TherapyRESULTS
Differentiation of hiPSCs into RPE
Using a modified protocol, we induced hiPSC-RPE from
hiPSCs (253G1; Nakagawa et al., 2008) that expressed the
pluripotency markers OCT3/4, NANOG, SSEA4, TRA-1-
60, and alkaline phosphatase (Figure 1A). Three weeks after
differentiation was initiated, pigmented colonies with
a typical RPE cobblestone appearance formed (Figure 1B).
To obtain pure populations of these cells, we manually
transferred the pigmented colonies and cultured them un-
til they became confluent (Figure 1C). The pigmented cells
had the structural characteristics of RPE including abun-
dant apical microvilli, adherens junctions, and tight junc-
tions under transmission electron microscopy (Figure 1D).
Additionally, the pigmented cells expressed typical RPE
markers associated with the retinoid cycle (RPE65 [Gu
et al., 1997; Marlhens et al., 1997] and CRALBP [Maw
et al., 1997]), phagocytosis (MERTK [Gal et al., 2000]),
and chloride channels (BEST1 [Stone et al., 1992]) as de-
tected by RT-PCR (Figure 1E), and eye field specification
markers (PAX6 and MITF), BEST1, RPE65, and a tight junc-
tion marker (ZO-1) on immunocytochemistry (Figure 1F).
Production of hiPSC-RPE Cell Sheets with No Artificial
Scaffold
To produce hiPSC-RPE cell sheets without any artificial
scaffold, we seeded hiPSC-RPE onto type I collagen gel onFigure 1. Generation of hiPSC-RPE and hiPSC-RPE Cell Sheets from
(A) Phase-contrast image and immunostaining for the pluripotency m
of hiPSCs. Scale bar, 200 mm.
(B) Low-power images of a 6 cm dish containing hiPSCs 3 weeks afte
(C) Low-power (left panel) and phase-contrast (right panel) images o
seeding. Scale bar, 200 mm.
(D) Transmission electron microscopy image of abundant apical microv
pigmented cells.
(E) RT-PCR analysis of typical RPE markers in iPSCs (253G1), iPSC-R
hiPSC-RPE cell sheets (253G1 and 59SV9) expressed typical RPE marke
collagen gel.
(F) Immunostaining for typical RPE markers (PAX6, MITF, BEST1, RPE
(G) Schematic image showing the procedure for culture of iPSC-RPE o
(H) Schematic image showing the procedure for iPSC-RPE cell sheets
(I) Low-power (left panel) and phase-contrast (right panel) images o
confluent on the collagen gel. Scale bars, 50 mm.
(J) Low-power image of the Transwell insert after the insert membra
(green) of hiPSC-RPE on the collagen gel before collagenase treatmen
(K) Low-power image of the Transwell insert after collagenase treatmen
RPE on the collagen gel after collagenase treatment (right panel). The
immunohistochemistry.
(L) Low-power image of a released hiPSC-RPE cell sheet.
(M) Low-power image of grafts made by cutting the cell sheet using
(N) Immunostaining for basementmembrane (laminin and type IV colla
See also Movies S1, S2, and S3.
Stem Cella Transwell insert. Typically, hiPSC-RPE became confluent
on the collagen gel within 2 weeks after seeding, and
confluent hiPSC-RPE formed a pigmented monolayer
sheet with a characteristic RPE cobblestone appearance
(Figure 1I). One and 4 weeks after reaching confluence,
the hiPSC-RPE cell sheets expressed typical RPE markers
(RPE65, CRALBP, MERTK, and BEST1) on RT-PCR
(Figure 1E).
After the sheets reached confluence, we removed an
insert membrane and applied a collagenase from the bot-
tom to dissolve the collagen gel (Figures 1J and 1K), and
then cut the margin of the hiPSC-RPE to release it as cell
sheet from the insert (Figure 1L). The hiPSC-RPE cell sheets
were approximately 1 cm in diameter, which is large
enough to cover AMD lesions in the macula about 3 mm
in diameter, and retained their sheet structure (Movie S1
available online). The collagen gel initially used as a tempo-
rary scaffold was substantively removed by collagenase
treatment, as shown by immunohistochemistry (Figures
1J and 1K). The procedure is summarized in Figures 1G
and 1H. We prepared grafts by cutting cell sheets into the
desired size and shape using a laser microdissection
(LMD) system (Figure 1M; Movie S2). These grafts ex-
pressed an extracellular matrix of basement membrane
(laminin and type IV collagen) and ZO-1 on immunohisto-
chemistry (Figure 1N), and remained intactwhen subjected
to manipulations required for the transplantation proce-
dure (Movie S3).hiPSCs
arkers OCT3/4, NANOG, SSEA4, TRA-1-60, and alkaline phosphatase
r initiation of differentiation.
f a 12-well dish containing third-passage hiPSC-RPE 4 weeks after
illi (left panel) and adherens and tight junctions (right panel) in the
PE (253G1), iPSC-RPE cell sheets (253G1 and 59SV9), and hRPE.
rs 1 week (1w) and 4 weeks (4w) after they reached confluence on
65, and ZO-1) in the pigmented cells. Scale bars, 50 mm.
n the collagen gel.
.
f the Transwell insert containing hiPSC-RPE cell sheets that became
ne was removed (left panel). Immunostaining for type I collagen
t (right panel). The collagen gel is positive for collagen I (green).
t (left panel). Immunostaining for type I collagen (green) of hiPSC-
collagen gel is completely eliminated using collagenase I (green) in
the LMD system.
gen) and tight junction (ZO-1)marker in the grafts. Scale bar, 20mm.
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In Vitro and In Vivo
We investigated whether the hiPSC-RPE exhibited func-
tions typically observed in native RPE. RPE is known to
secrete a range of growth factors, including pigment
epithelium-derived factor (PEDF; Steele et al., 1993) and
VEGF (Adamis et al., 1993), and to contribute to blood-
retinal barrier function. Using ELISA, wemeasured concen-
trations of PEDF and VEGF in conditioned hiPSC-RPE
medium exhibiting different grades of pigmentation (low,
medium, and high). We evaluated barrier function by
measuring the transepithelial electrical resistance (TER; Ste-
venson et al., 1986), which provides a simple and sensitive
method for the detection of functional tight junctions. On
the dish, hiPSC-RPE secreted PEDF and VEGF, increasing as
the intensity of the pigmentation increased (Figure 2A),
and hiPSC-RPE on the Transwell insert showed a high
TER in a time-dependent manner (Figure 2B). We next
measured the TER and concentration of PEDF and VEGF
in apical and basal media of hiPSC-RPE grown on the
collagen gel in the inserts 4 weeks after they became
confluent. The mean TER was approximately 290 Ucm2
and the concentration of PEDF was higher in the apicalFigure 2. Functional Assessment of hiPSC-RPE Cell Sheets In Vitr
(A) ELISA of PEDF and VEGF secretion by hiPSC-RPE (253G1) on the di
VEGF: low 3.07, medium 4.6, high 9.38 ng/106 cells/24 hr). Right pa
grades of pigmentation (upper panel is low pigmentation, middle pan
(B) TER of five hiPSC-RPE cell sheets (253G1) on Transwell inserts at
(C) TER and concentration of PEDF and VEGF in apical and basal medi
collagen gel in the Transwell insert. hiPSC-RPE (253G1; n = 3), PEDF: a
5.44 ± 0.65, basal 17.22 ± 0.27 ng/well/24 hr, TER: 287 ± 18 Ucm2.
25.6 ng/well/24 hr, VEGF: apical 4.18 ± 0.44, basal 15.95 ± 2.33 ng
apical 465.8 ± 21.2, basal 206.8 ± 35.0 ng/well/24 hr, VEGF: apical 3
hiPSC-RPE (K21S4; n = 9), PEDF: apical 120.0 ± 15.7, basal 40.6 ± 9.2
24 hr, TER: 176 ± 32 Ucm2. hRPE (n = 3), PEDF: apical 272.8 ± 20.8
3.93 ± 0.37 ng/well/24 hr, TER: 167 ± 23 Ucm2.
(D) DAPI-stained sections. Images of hiPSC-RPE cell sheet transplan
(arrowhead) around the graft (arrow).
(E–G) Confocal images of RCS rat eyes. Scale bar, 50 mm.
(E) Immunostaining for rhodopsin (red) in nontransplanted eye sect
(F) Immunostaining for rhodopsin (red, left panel) and ZO-1 (green,
(G) Immunostaining for rhodopsin (red) and ZO-1 (green) in transpla
graft (asterisk) was preserved for a thickness of five cell rows, and th
border of the graft. Scale bar, 50 mm. Immunostaining for rhodopsin (
right panel). The transplanted cell fragment is positive for anti-huma
(H) Immunohistochemical analyses of 12-week-old RCS rats. The ONL
K21S4; n = 7) and cell suspension (n = 6) in the transplanted eyes w
transplanted (n = 13) eyes. The ONL situated above transplanted c
transplantation was almost completely lost.
(I) Left panel: average scotopic responses to single flashes were reco
eyes) and transplantation of hiPSC-RPE cell sheet (56 ± 22 mV; n = 3 ey
eyes have reduced a- and b-waves, and sham eyes have only a negative
the preventive effect of transplantation.
All pooled data are represented as mean ± SEM; asterisks (*) indicate
Stem Cellthan in the basal medium, whereas that of VEGF was
higher in the basal than in the apical medium (Figure 2C).
Furthermore, we obtained consistent results with regard
to expression of typical RPE markers, polarized secretion
of PEDF and VEGF, and high TER with three different
hiPSC-RPE lines (59SV3, 59SV9, and K21S4) generated
from fibroblasts harvested from a patient with retinitis pig-
mentosa (RP), as well as from commercially available hu-
man fetal RPE (hRPE) used as a control (Figures 1E and 2C).
To assess the function of hiPSC-RPE cell sheets (253G1,
59SV9, and K21) in vivo, we transplanted fragments of
sheets into the subretinal space of pink-eyed Royal College
of Surgeons (RCS) dystrophic rats, an animal model of in-
herited retinal degeneration (Mullen and LaVail, 1976).
RCS rats carry a mutation in the Mertk gene that results in
defective phagocytosis of photoreceptor outer segments
by RPE, and lose their photoreceptor cells by approxi-
mately 3 months after birth (Dowling and Sidman, 1962).
It has been reported that transplantation of normal RPE
into the subretinal space of RCS rats at an early age pre-
serves photoreceptor cells around the grafted cells (Li and
Turner, 1988). We transplanted 1 3 1 mm hiPSC-RPE cell
sheets, including 1.42 3 104 cells (live cells: 1.32 3 104o and In Vivo
sh (PEDF: low 386.2, medium 478.5, high 658.1 ng/106 cells/24 hr;
nels show phase-contrast images of hiPSC-RPE exhibiting different
el is medium pigmentation, and lower panel is high pigmentation).
7 weeks after seeding.
a of hiPSC-RPE (253G1, 59SV3, 59SV9, and K21S4) and hRPE on the
pical 751.0 ± 100.0, basal 379.7 ± 46.4 ng/well/24 hr, VEGF: apical
hiPSC-RPE (59SV3; n = 3), PEDF: apical 415.0 ± 29.7, basal 215.0 ±
/well/24 hr, TER: 250 ± 61 Ucm2. hiPSC-RPE (59SV9; n = 5), PEDF:
.44 ± 0.39, basal 10.84 ± 1.75 ng/well/24 hr, TER: 314 ± 26 Ucm2.
ng/well/24 hr, VEGF: apical 1.23 ± 0.31, basal 5.03 ± 0.92 ng/well/
, basal 135.8 ± 5.6 ng/well/24 hr, VEGF: apical 2.80 ± 0.16, basal
tation in a 12-week-old RCS rat, showing preservation of the ONL
ion.
right panel) in sham-surgery eye section.
nted eye section (left panel). The ONL (arrow) situated above the
e ONL (arrowhead) with the debris zone was preserved beyond the
red) and EMMPRIN (green) in transplanted eye section (center and
n EMMPRIN. Scale bar, 20 mm.
thickness of the hiPSC-RPE cell sheet (253G1; n = 27; 59SV9; n = 12;
as significantly greater than in either the sham (n = 27) or non-
ells was five cell rows. In contrast, the ONL in the eyes without
rded in 9-week-old RCS rats after sham injection (13 ± 5 mV; n = 7
es) and cell suspension (78 ± 10 mV; n = 4 eyes). Both transplanted
component. Right panel: b-wave amplitude of each RCS rat, showing
statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001).
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24), or hiPSC-RPE cell suspension into the subretinal space
of 3-week-old RCS rats. Six weeks later, we recorded electro-
retinograms (ERGs), and 9 weeks later, we measured the
thickness of the retinal photoreceptor layer, i.e., the outer
nuclear layer (ONL) (Figure 2D). RCS rats were adminis-
tered cyclosporine to prevent rejection, and consequently
no signs of rejectionwere observed around the transplanta-
tion sites. In nontransplanted eyes, the ONL was nearly
completely lost, and immunostaining for rhodopsin was
restricted to a debris zone of outer segments shed by the
photoreceptors (Figure 2E). In contralateral eyes subjected
to sham surgery, the ONL was approximately 1–2 cell
rows thick and the outer limiting membrane containing
ZO-1 was not detected (Figure 2F). In transplanted eyes,
the ONL situated above hiPSC-RPE cell sheets, which is
positive for EMMPRIN of human origin, was preserved
with a thickness of five cell rows, and the ONL with the
debris zone was preserved beyond the border of the graft
(Figure 2G). The outer limiting membrane was also pre-
served around the graft. This result was consistent among
the hiPSC-RPE cell sheets derived from any of the hiPSC
lines tested. We also obtained similar results with trans-
plantation of hiPSC-RPE cell suspension (253G1, 1.0 3
105 cells). ONL thickness in the transplanted RCS rat group
was significantly greater than that in either the sham or the
nontransplanted group (Figure 2H). In addition, transplan-
tation of hiPSC-RPE cell sheet and cell suspension both
significantly restored ERG responses in RCS rats (Figure 2I),
and none of the transplanted cells showed tumor forma-
tion. These results indicate that hiPSC-RPE cell sheets
show characteristics similar to those of native RPE both
in vitro and in vivo.
Gene Expression of hiPSC-RPE
We previously generated hiPSCs from patients with RP
using retrovirus (59M8, K10M15, K11PD17, K21S4, and
K31M28) and Sendai virus (59SV3, 59SV4, and 59SV9) vec-Figure 3. Gene Expression of hiPSC-RPE
(A) Phylogenetic tree of classified hiPSC-RPE, hiPSCs, and fibroblast
54,675 probe sets using microarray data. The phylogenetic tree shows
near the native hRPE cluster. Bootstrap values are noted near the bran
(B) Heatmap of 154 genes selected as RPE signature genes in 12 h
consistently showed similar patterns of gene expression irrespective o
their differentiation into RPE.
(C) Scatterplot of normalized expression logarithmic values of the 154
with hRPE. Each gene is represented by a point (black point for the ge
populations; red and blue points for the genes that change more than
that almost all of the genes had similar expression (black points) with
levels. ARPE19 showed 116 genes with similar expression (black points
and BEST1, with lower expression.
See also Table S1.
Stem Celltors, which we differentiated into hiPSC-RPE using two
different methods (stromal cell-derived inducing activity
[SDIA] [Kawasaki et al., 2002] and serum-free culture
of embryoid body-like aggregates [SFEB] [Osakada et al.,
2008; Watanabe et al., 2005]). To investigate whether these
hiPSC-RPE colonies showed gene-expression patterns
similar to those of native RPE, we classified hiPSC-RPE,
hiPSCs, and fibroblasts from RP patients, hRPE, ARPE19
(a human RPE cell line), and other human tissues from
54,675 probe sets using microarray data. By performing hi-
erarchical clustering analysis on these cells, we were able to
generate a phylogenetic tree in which each cell type was
separated independently and all hiPSC-RPEs were grouped
near the native hRPE cluster (Figure 3A). All data are avail-
able from the Gene Expression Omnibus (GEO) repository
at the National Center for Biotechnology Information
(NCBI) archives Series (GSE50738, http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE50738).
We next examined the expression of 154 genes selected
as RPE signature genes (Strunnikova et al., 2010) in 12
hiPSC-RPE lines, three hRPE lines, and ARPE19. Figure 3B
shows a heatmap of the expression of these 154 genes in
the above cell lines. All hiPSC-RPEs consistently showed
similar patterns of gene expression irrespective of the
patient or the methods used to generate the hiPSCs and
induce their differentiation into RPE. We then compared
the expression of these 154 genes in hiPSC-RPE or
ARPE19 with hRPE as native RPE. The RPE signature genes
in each hiPSC-RPE showed expression patterns serum-
free suspension to that of hRPE, whereas many genes in
ARPE19, including critical genes such as RPE65 and
BEST1, showed lower expression than those in hRPE lines
(Figure 3C; Table S1).
Immunogenicity of iPSC-RPE In Vitro and In Vivo
A major cause of RPE transplantation failure in clinical
practice is graft rejection; however, autologous grafts of
hiPSC-RPE are expected to be nonimmunogenic, givens from RP patients, hRPE, ARPE19, and other human tissues from
each cell type separated independently, with all hiPSC-RPE grouped
ches (maximum parsimony above and maximum likelihood below).
iPSC-RPE lines, three hRPE lines, and ARPE19. All hiPSC-RPE lines
f the patient or the methods used to generate the hiPSCs and induce
genes in hiPSC-RPE (59, K11, K21, and K31) and ARPE19 compared
nes that do not change more than three times between the two cell
three times between the two cell populations). hiPSC-RPE showed
hRPE, and only two to four genes (blue points) had low expression
), and 43 genes (blue points), including critical genes such as RPE65
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recipient. We first examined the expression of major
histocompatibility complex (MHC) proteins, which play
an important role in mediating immune response, on the
surfaces of graft cells to examine the potential immunoge-
nicity of iPSC-RPE in vitro. hiPSCs expressed low levels of
MHC class I (MHC-I) and b2-microglobulin (b2-MG) pro-
teins (Figure 4A), which increased upon differentiation
(Figure 4B). Since RPE transplantation surgery may induce
some degree of inflammation, we examined the effect of
the proinflammatory cytokine interferon-gamma (IFN-g)
on the surface expression of these proteins in hiPSCs and
hiPSC-RPE. Addition of IFN-g increased the expression of
MHC-I and b2-MG on hiPSCs (Figure 4A), and slightly
upregulated the expression of MHC-II on hiPSC-RPE (Fig-
ure 4B). Other hiPSCs, hiPSC-RPE (59SV9), and hRPE
yielded similar results (Figure S1). Hence, grafts of alloge-
neic hiPSC-RPE may be rejected in a manner similar
to that observed in fetal RPE transplantation. We next
prepared iPSC-RPE (Okamoto and Takahashi, 2011) from
cynomolgus monkey (Macaca fascicularis) somatic cells
(miPSC-RPE) and transplanted them into the eyes of recip-
ientmonkeys to examine the immunogenicity of iPSC-RPE
in vitro and in vivo. We first examined the expression of
MHC-I and MHC-II on miPSC-RPE (Cyn46). As expected,
miPSC-RPE constitutively expressed MHC-I, but not
MHC-II (Figure 4C). On the other hand, IFN-g-treated
miPSC-RPE expressed MHC-II. As next step, to confirm
that the MHC mismatch between peripheral blood mono-
nuclear cells (PBMCs) and allogeneic iPS-RPE cells in mon-
key were sufficient to elicit strong allogeneic responses,
PBMCs were isolated from two monkeys (Cyn46 [auto-
genic] and Cyn51 [allogeneic]) and cultured with miPSC-
RPE (Cyn46) in the presence or absence of anti-monkey
CD3 antibody. To avoid nonspecific T cell proliferation,Figure 4. Immunogenicity of iPSC-RPE In Vitro and In Vivo
(A–C) Mean fluorescence intensity of MHC antigens in hiPSCs (A; 253G1
and pluripotency marker (SSEA4) in hiPSCs (A). The red line histogra
indicate that the percentage of positive cells determined by isotype-
(D) Lymphocyte reactions of autogenic or allogeneic miPSC-RPE. mi
Cyn46 autogenic or Cyn51 allogeneic monkey. In right panels, anti-mo
24 hr. CFSE-labeled PBMCs were analyzed by flow cytometry. Numbers
(E–G) Transplantation of miPSC-RPE cell suspension into the subretina
3 days (3d; F) and 7 days (7d; G) after surgery.
(E) Transplanted cells were observed in the macular area (arrowhead, r
the vitreous cavity (arrow, right panel). Transplanted cells could not
(F and G) Transplanted cells accumulated at the lower margin of the in
transplanted cells refluxed into the vitreous cavity (arrow).
(H) Image of autologous miPSC-RPE cell sheet (red arrow) transplanta
hyperfluorescence (white arrowhead) on FA around the engrafted
over artificial retinal detachment (red arrowhead) 1 year after surg
fluorescence on FA.
See also Figures S1 and S2.
Stem Cellanti-CD3 antibodies were used after 24 hr of culture. The
results showed that Cyn46 PBMCs did not induce prolifer-
ation of miPSC-RPE, whereas Cyn51 allogeneic PBMCs
induced proliferation (Figure 4D), indicating that an
MHC disparity between lymphocytes and allogeneic
iPSC-RPE can induce immune responses. These results sug-
gest that lymphocytes may directly attack MHC antigens
on iPSC-RPE after transplantation. However, an MHC
match between lymphocytes and RPE cannot induce im-
mune responses. To date, RPEs have been clinically trans-
planted as either a cell suspension or RPE-choroid sheets.
We compared the outcomes of miPSC-RPE cell suspension
and cell sheets transplanted into the subretinal space in
monkeys. For cell-suspension transplantation, we intro-
duced Venus (a variant of yellow fluorescent protein) into
miPSC-RPE using a lentivirus produced in 293T packaging
cells (Miyoshi et al., 1998) to trace the transplantedmiPSC-
RPE after surgery using a fluorescein angiography (FA) cam-
era. Although miPSC-RPE were observed in the macular
area due to the supine position of the animals immediately
following surgery (Figure 4E), these cells accumulated at
the lower margin of the induced retinal detachment by
7 days after surgery (Figures 4F and 4G). In addition,
some transplanted cells were refluxed into the vitreous cav-
ity, which is major cause of proliferative vitreoretinopathy,
a severe complication. In contrast, transplanted miPSC-
RPE cell sheets were observed without Venus introduction
after surgery, situated on the transplanted site. In RPE
transplantation, cell sheets thus demonstrate a number of
advantages, including graft control, less dispersion, and
traceability.
We next transplanted 1 3 2 mm miPSC-RPE cell sheets
as three allografts and one autograft into the subretinal
space of four monkeys without immunosuppression and
observed themonkeys for 1 year. Briefly, iPSCswere derived), hiPSC-RPE (B), and miPSC-RPE (C; Cyn46) with and without IFN-g
ms represent isotype control antibodies. Numbers in the histogram
specific control was less than 0.5%.
PSC-RPE (Cyn46) were cocultured with CFSE-labeled PBMCs from a
nkey CD3 antibody was used in cultures for PBMCs plus iPS-RPE after
in the histogram indicate CFSE-positive cells.
l space of a monkey immediately following surgery (0d; E) and then
ight panel) using FA, and some transplanted cells were refluxed into
be observed by color fundus photography after surgery (left panel).
duced retinal detachment by 7 days after surgery (arrowhead). Some
tion, showing depigmentation (around the red arrow) and moderate
graft, comparable to the hyperfluorescence commonly observed
ery. The injection site (blue arrow) also showed moderate hyper-
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cell sheets; the iPSC donor also served as the sole autograft
recipient (Cyn46). The other three monkeys (Cyn51,
Cyn54, and P170), which were MHC mismatched to
the iPSC donor, were transplanted with the allogeneic
miPSC-RPE cell sheets. In the allograft, typical signs of graft
rejection, such as formation of whitish fibrous tissues,
leakage of fluorescein on FA, and hyperreflective material
under the retina or retinal edema on optical coherence
tomography (OCT), were detected around the grafts (Fig-
ure S2). In contrast, in the autograft transplant, we found
only slight depigmentation of the engrafted RPE and mod-
erate hyperfluorescence on FA around the graft, compara-
ble to the hyperfluorescence commonly observed over
artificial retinal detachment 1 year after surgery (Figure 4H).
We conclude that the autograft showed no rejection
signs and none of the transplanted cells showed tumor
formation.DISCUSSION
In this study, we report the production of hiPSC-RPE cell
sheets without any artificial scaffold. These hiPSC-RPE
cell sheets exhibit the morphological properties, in vitro
and in vivo function, gene expression, and immunoge-
nicity of authentic RPE, as well as the structural rigidity
needed to withstand the physical stresses associated with
the transplant procedure, suggesting they may show safety
and utility suitable for human clinical research and
application.
Considerable attention has been paid to the potential of
hiPSCs as a cell source for regenerative medicine, disease
modeling, and drug testing, and research into the use of
PSC-derived cells in regenerative medicine has made rapid
advances in recent years. Transplantation of RPE derived
from PSCs for use in the potential treatment of diseases
such as AMD represents a first-line research target in this
field. The rationales underlying this approach include the
following: (1) Limitations of the available treatments for
AMD, such as anti-VEGF therapy and photodynamic ther-
apy, which treat choroidal neovascularization but not the
underlying RPE degeneration in advanced AMD, have led
to attention being given to alternative approaches inwhich
pathological RPE is replaced by healthy RPE. (2) RPE consist
of pigmented cells that have a typical cobblestone appear-
ance and form colonies during differentiation, thus
providing visual cues to facilitate purification. (3) The
number of cells needed for a lesion site is small compared
with that needed for many other forms of proposed cell
therapy (Mason and Dunnill, 2009). (4) iPS-RPE cells are
readily functional in vitro and do not require specified inte-
gration into the neural network or further maturation214 Stem Cell Reports j Vol. 2 j 205–218 j February 11, 2014 j ª2014 The Ain vivo. (5) Clinical studies of fetal or autologous RPE cell-
sheet transplantation have shown some degree of efficacy,
although problems of rejection (Algvere et al., 1994) or
invasive harvesting (Binder et al., 2002; van Meurs and
Van Den Biesen, 2003) remain. Transplantation of an RPE
suspension derived from human ESCs, which are similar
in many ways to hiPSCs, is being tested in a clinical trial
(Strunnikova et al., 2010). Given these merits, we suggest
that the generation of autologous RPE cell sheets that
are very highly similar to native RPE in vitro may represent
a very attractive option for cell transplantation therapy
in AMD.
The hiPSC-RPE cell sheets made by our protocol are
cellular monolayers and maintain their structure using
both tight junctions and a basement-membrane-like
structure that is positive for laminin and type IV collagen,
which in native RPE collectively form the basement mem-
brane. The collagen gel initially used to make hiPSC-RPE
cell sheets is type I collagen, and the collagen gel was
removed by the collagenase I treatment, which dissolves
collagens I, II, and III, but not collagen IV, indicating
that our grafts contain purely autonomously produced
collagen IV and laminin. Several groups have reported
the use of artificial scaffolds to maintain RPE cell sheets
in monolayer, but biodegradable materials often cause
inflammation, and nondegradable membranes may inter-
fere with physiological interactions between the choroid
and the RPE with overlying photoreceptors. Comparing
RPE cell suspension with RPE cell sheet, a previous
report showed that harvested autologous RPE suspension
did not survive at the lesion site of AMD patients, while
RPE around the harvested area proliferated and covered
the defective area. The RPE and Bruch’s membrane,
including a collagen-, elastin-, and laminin-rich extra-
cellular matrix in the lesion site of AMD patients, is
impaired, suggesting that transplanted RPE need extra-
cellular matrix, collagen IV, and laminin to engraft. In
addition, grafts in the form of sheets have advantages in
protecting cells from apoptosis and allowing the manipu-
lative control of grafts, as shown in Figure 4. Thus, the
hiPSC-RPE cell sheets with their own basement-mem-
brane-like structure described in this report may offer
advantages over RPE suspensions and RPE cell sheets
with an artificial scaffold.
Our hiPSC-RPE cell sheets met general requirements, in
terms of quality, quantity, consistency, and safety, for clin-
ical-grade donor cells intended for use in cell replacement
therapy. These cell sheets expressed typical RPE markers,
showed polarized secretion of PEDF and VEGF, and ex-
hibited phagocytotic activity similar to that of native
RPE in vivo. With regard to graft survival, we confirmed
that the grafted hiPSC-RPE cell sheets were positive for
anti-human antibody for at least up to 9 weeks afteruthors
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of quantity, it is simple to obtain a sufficient amount of
RPE from hiPSCs for transplantation into an AMD patient.
Our protocol may require only a relatively small-scale cul-
ture system, which may also be an advantage considering
the processes required in Good Manufacturing Practice
(GMP) facilities. A hiPSC-RPE sheet with a diameter of
1 cm can be generated from 5 3 105 cells, which is suffi-
cient to cover a macular area with a diameter of 3 mm.
RPE generated by our protocol proved to be consistent,
as shown by a cluster analysis of microarray data, in
which hiPSC-RPE differentiated from various cell lines
by various methods uniformly clustered in a group
near that of human fetal RPE. Moreover, strikingly similar
expression patterns of 154 RPE ‘‘hallmark’’ genes were
observed in all 12 hiPSC-RPEs tested. In addition, 20
hallmark genes showed consistently higher expression
levels in all 12 hiPSC-RPEs than in fetal RPE. Nine of these
genes, including two mature RPE genes (RPE65 and
BEST1), indicated the developmental stage, which was
reported to be more highly expressed in adult native
RPE than in fetal native RPE (Strunnikova et al., 2010).
Conversely, two genes that had higher expression in fetal
native RPE (COL8A2, which affects collagen type VIII, and
DCT, which affects biosynthesis of melanin) did not seem
to have a relation to RPE maturation. These results indi-
cate that hiPSC-RPE is nearer to the adult RPE stage. Lastly,
safety remains the major concern confronting the devel-
opment of hiPSC-derived clinical products, as contam-
ination of grafts by residual hiPSCs may result in the
formation of teratomas, a form of benign tumor. We
were able to purify RPE efficiently by a series of ‘‘pick
up and expand’’ procedures, taking advantage of RPE
cells’ unique morphology. Furthermore, to our knowl-
edge, there have been no reports in the literature of tu-
mors of RPE origin. To confirm that hiPSC-RPE purified
by our method showed no contamination by significant
numbers of hiPSCs, we used quantitative PCR of Lin28.
This method is capable of detecting a single iPSC from a
50,000-cell colony (Kuroda et al., 2012), which is signifi-
cantly lower than the number of undifferentiated cells
needed to induce tumor formation (data not shown).
We also did not observe any tumor formation in vivo
following injection of purified hiPSC-RPE cell sheets and
suspension in RCS rats for 9 weeks, hiPSC-RPE cell sheets
in monkeys for 1 year (Figures 2 and 4), or 1 3 1 mm
hiPSC-RPE cell sheets in the subretinal space of immu-
nodeficient mice for 60 weeks (H.Kanemura, M. Go,
M. Shikamura, N. Nishihita, N. Sakai, H.K., M. Mandai,
M. Takahashi, and S. Kawamata, unpublished data).
Once the use of hiPSC-derived RPE has been justified in
clinical practice, a variety of customized transplantation
approaches may be developed in the future. For diseasesStem Cellsuch as exudative AMD, in which the blood-retinal barrier
is disrupted, autografts derived from the recipient would
presumably be more suitable. There may also be cases,
such as RPE tear, in which allograft transplantation would
be more appropriate. The use of selected cell lines would
also clearly bemore cost-efficient in the event that demand
for cell transplants increases. The ocular space has histori-
cally been thought of as an immunoprivileged site, and
in pathologies in which barrier function is maintained,
allografts may be accepted by the host tissue, as evidenced
by reports that human fetal RPE (Algvere et al., 1994)
and hESC-RPE (Schwartz et al., 2012) transplants in
patients with dry-type AMD and Stargardt’s disease were
not rejected. For these purposes, a cell bank of iPSC lines
withmultiple human leukocyte antigen types may provide
a good system for more widespread applications of RPE
transplantation. In addition, advances in clinical imaging
techniques, such as OCT and fundus autofluorescence
(Schmitz-Valckenberg et al., 2009), have enabled the detec-
tion of early pathologic changes. In cases in which hESCs
or hiPSC-RPE cells are transplanted for early dry-type
AMD or for prevention of wet-type AMD, for instance,
transplantation of RPE cell suspension may be a better
option, in order tominimize surgical invasion. Cell suspen-
sion had an equivalent effect in our data (Figure 2H), and
the effectmay reflect the coverage area of transplanted cells
(Figure 2I). Additionally, RPE cell sheets using artificial
scaffolds may one day be engineered to provide additional
benefits, such as the secretion of supplemental neurotro-
phic factors.
In summary, the advantages of our RPE cell sheets in
comparison with cell suspension include morphological
and physiological similarities to native RPE, solid coverage
of the lesion, and traceability after transplantation; how-
ever, we still need to scale up and reduce the costs of
manufacturing. Additionally, the avoidance of artificial
scaffolds is ideal, since artificial scaffolds often cause
inflammation. The use of auto-hiPSCs provides the advan-
tage of minimizing the risk of graft rejection, especially
in diseases with a disrupted blood-retinal barrier, such as
wet-type AMD. A disadvantage of sheet transplantation
compared with cell-suspension transplantation is that it
requires a more complicated, invasive surgical procedure,
and we are trying to resolve this issue by refining the
transplantation method.
We recently finished preparing hiPSC-RPE cell sheets in
a GMP-grade cell-processing facility based on the method
described in this study, and confirmed the consistent repro-
ducibility of the results, as well as the safety of the cell
sheets for clinical application. We hope that the prelimi-
nary data shown in the present study provide useful infor-
mation for the advancement of future RPE replacement
therapies.Reports j Vol. 2 j 205–218 j February 11, 2014 j ª2014 The Authors 215
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Culture of hiPSCs and hiPSC-RPE
The methods used for hiPSC maintenance and differentiation
were described previously (Haruta et al., 2004; Kawasaki et al.,
2002; Osakada et al., 2008). The hiPSC line 253G1 (Nakagawa
et al., 2008), made from healthy human dermal fibroblast cells,
was purchased from RIKEN BioResource Center. Another iPSC
line was made by our group from dermal fibroblasts of a patient
with RP (with a photoreceptor-specific gene mutation) by retro-
viral (59M8, K10, K11, K21, and K31) and Sendai viral (59SV3,
59SV4, and 59SV9) introduction of OCT3/4, SOX2, c-MYC, and
KLF4, and maintained as previously described (Jin et al., 2012).
For details, see Supplemental Experimental Procedures.
Culture of Nonhuman Primate iPSCs and iPSC-RPE
miPSCs and iPSC-RPE were made from cynomolgus monkeys
(Japan Biological Science) as previously described using OCT3/4,
SOX2, c-MYC, and KLF (Okamoto and Takahashi, 2011). For
details, see Supplemental Experimental Procedures.
Preparation of Human and Nonhuman Primate
iPSC-RPE Cell Sheets without any Artificial Scaffold
Collagen gel was prepared on ice using the Collagen Gel Culture
Kit (Nitta Gelatin) according to the manufacturer’s instruc-
tions. Briefly, acid-solubilized porcine tendon collagen type I-A
(3 mg/ml, Cellmatrix; Nitta Gelatin), 53 concentrated Dulbecco’s
modified Eagle’s medium (DMEM; Nitta Gelatin), and reconstitu-
tion buffer (NaOH 50 mM, NaHCO3 260 mM, HEPES 200 mM;
Nitta Gelatin) were gently mixed in a ratio of 7:2:1 on ice, and
this collagen solution was added on the Transwell insert, polymer-
ized at 37C for 30 min, and incubated in RPE cell sheet medium
(F10 culture medium [Sigma] and 10% fetal bovine serum) over-
night. The next day, iPSC-RPE (5 3 105 cells/500 ml/well) were
seeded on the collagen gel and cultured in RPE cell sheet medium.
After reaching confluence, the iPSC-RPE were cultured in serum-
free retinal medium supplemented with 10 ng/ml basic fibroblast
growth factor and SB431542 (0.5 mM) for at least 4 weeks. The
medium was changed every 2–3 days.
To prepare iPSC-RPE cell sheets without any artificial scaffold, we
removed the insert membrane and applied a collagenase I (Roche)
at 37C for 30 min to dissolve the collagen gel, and then cut the
margin of the hiPSC-RPE to release it from the insert as an intact
cell sheet. The hiPSC-RPE cell sheets were washed in PBS and trans-
ferred to a dish for LMD (Lumox-35; Greiner). These sheets were
kept moist with DMEM/F12 (200 ml) until they were cut using
LMD (PALM MicroBeam; Zeiss) according to the manufacturer’s
instructions.
Microarrays
RNA was extracted from hiPSC-RPE, hRPE, ARPE19, hiPSCs, and
fibroblasts using TRIzol (Invitrogen) and purified by RNeasy
(QIAGEN). Labeled aRNA was generated from total RNA using a
30 IVT Express Kit (Affymetrix) and then hybridized to expression
microarrays (Human Genome U133 Plus 2.0 Array; Affymetrix).
Labeling, hybridization, signal detection, and analysis were
performed by the CDB Gene Chip Service. hRPE (hRPE1, lot-216 Stem Cell Reports j Vol. 2 j 205–218 j February 11, 2014 j ª2014 The A0F3237; hRPE2, lot-0F32920; and hRPE3, lot-181239) were




The care and maintenance of the rats conformed to the ARVO
statements for the Use of Animals in Ophthalmic and Vision
Research, and the Use of Laboratory Animals, as well as the Guide-
lines of the RIKEN CDB Animal Experiment Committee. The ani-
mals were housed in rooms under standard laboratory conditions
(18–23C, 40%–65% humidity, 12 hr light/12 hr dark cycle),
with food and water available ad libitum. Animals were anesthe-
tized with a mixture of ketamine and xylazine, and their pupils
were dilated with 0.5% tropicamide and 0.5% phenylephrine
hydrochloride.
Transplantation of hiPSC-RPE Cell Sheets into the
Subretinal Space of RCS Rats
Pink-eyed dystrophic RCS (Jcl-rdy/rdy, p-) rats were purchased
from CLEA Japan and maintained as described previously (Haruta
et al., 2004). For transplantation, we made a small scleral incision
using a 30-gauge disposable needle. Then, we injected 2 ml DMEM/
F12 (50:50) medium including a fragment of 13 1 mmhiPSC-RPE
cell sheets, hiPSC-RPE cell suspension including 1 3 105 cells, or
medium only as sham injection into the subretinal space of the
right eye of RCS rats using a 33-gauge needle. An equivalent
volume of DMEM/F12 medium was injected subretinally as sham
surgery in eight contralateral eyes. The other contralateral eyes
were classified as ‘‘no treatment.’’ Nine weeks after transplantation
(i.e., at 12 weeks age), the eyes were processed for histological eval-
uation. RCS rats were administered cyclosporine to prevent rejec-
tion, and consequently no signs of rejection were observed around
the transplantation sites.
Transplantation of miPSC-RPE Cell Suspension and
Cell Sheets into the Subretinal Space in Monkeys
Cynomolgus monkeys were purchased from Japan Biological
Science. miPSC-RPE were labeled with Venus produced from
a self-inactivating HIV-1-based lentivirus vector, CS-CDF-CMV-
Venus-PRE.
For transplantation of miPSC-RPE cell suspension, 5 3 104 cells
in 100 ml DMEM/F12 medium were injected into the subretinal
space. These cells were monitored through the FA barrier filter of
a color fundus camera (RetCamII; Clarity) immediately and then
3 and 7 days after surgery.
For transplantation ofmiPSC-RPE cell sheets, after induction of a
posterior vitreous detachment by active suction, a complete vitrec-
tomy (Accurus; Alcon) was performed. A localized retinal detach-
ment was created by intraocular irrigating solution (BSS Plus;
Alcon) using a subretinal injection cannula (rigid injection can-
nula; Synergetics). The transplantation site was enlarged to enable
implantation of graft, and another retinotomy site for drainage
was created by diathermy. A 13 2mmgraft inDMEM/F12medium
was transplanted using an outer tube of a 20-gauge indwelling nee-
dle (Terumo) attached to an extension tube (fluid tubing extension
kit; Eagle) of a 1 ml syringe (Terumo). After draining subretinaluthors
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rocarbon liquid (Alcon), we performed fluid-air exchange and
perfluoropane (ISPAN C3F8; Alcon) tamponade. These grafts were
monitored by means of color fundus pictures and FA (RetCamII;
Clarity) and OCT (Nidek) at 1, 2, and 4 weeks; 3 and 6 months;
and 1 year after surgery.
Statistical Analysis
The values are expressed as mean ± SEM, with p < 0.05 being
considered statistically significant. Secretion of PEDF and VEGF
was evaluated using paired t tests. One-way ANOVA followed by
Scheffe’s test was performed to compare the maximumONL thick-
ness and b-wave amplitudes of ERG among nontransplanted,
sham-transplanted, and transplanted animals to evaluate the
efficacy of treatment. Probability values < 5% were considered
significant.
For further details regarding the experimental procedures used in
this work, including cell culture, immunocytochemistry, immuno-
histochemistry, transmission electron microscopy, RT-PCR, ELISA,
fluorescence-activated cell sorting (FACS), TER, and ERG, see
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental
Procedures, two figures, one table, and three movies, and can
be found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2013.12.007.
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